Source: REPROHEALTH TECHNOLOGIES, INC. submitted to
BOVINE INTRAVAGINAL EMBRYO CULTURE DEVICE
Sponsoring Institution
National Institute of Food and Agriculture
Project Status
ACTIVE
Funding Source
Reporting Frequency
Annual
Accession No.
1031810
Grant No.
2024-33530-41954
Cumulative Award Amt.
$174,961.00
Proposal No.
2024-00402
Multistate No.
(N/A)
Project Start Date
Jul 1, 2024
Project End Date
Feb 28, 2025
Grant Year
2024
Program Code
[8.3]- Animal Production & Protection
Recipient Organization
REPROHEALTH TECHNOLOGIES, INC.
8435 CLEARVISTA PL
INDIANAPOLIS,IN 46256
Performing Department
(N/A)
Non Technical Summary
Efficient cattle production supports the livestock industry, 10s of thousands of farmers, and provides millions of people with important nutrition. Assisted Reproductive Technologies(ART) have been developed to improve cattle production. Bovine ART includes Artificial Insemination (AI), Embryo Transfer (ET), and In Vitro fertilization (IVF). The most advanced technology is IVF, yet it has the lowest embryo production rate because of technical and process problems. Poor efficiency leads to decreased farmersustainability and the production of poor-quality cows that may produce less milk or high-quality beef. Improving the production of genetically superior cows with multiple offspring will benefit the farmer, consumer, and environment.ReproHealth solves these problems with our novel bovine Intra Vaginal Embryo Culture (IVC) device. Embryos and grown in a small device, about the size of a thumb, in the cow's vagina. The device is taken out of the cow's vagina after 7 days and the embryos are transferred to recipient cows to establish a pregnancy. We will generate large amounts of data characterizing the quality of the embryos as compared to conventional IVF and we will publish this in scientific journals. We are targeting farmers that are currently doing IVF to maintain their herds and we are working with several key industry leaders to advance our technology. We see many benefits of this technology over Artificial Insemination and plan to show its superiority in the future.Ultimately we are developing a completely new form of cattle Assisted Reproductive Technology. This technology will 'bring the IVF lab tothe farm.' This advanced method of conception will lower the cost of production by improving the efficiency of embryo production and thus pregnancy. By getting multiple offspring of the cows with the best genetic traits, fewer cows will be needed to meet the customer demand. We feel strongly that we have a responsibility to help worldwide food insecurity with our technology. A technology that is easy to use and increases cattle production would give protein and milk to the millions of people who suffer from food insecurity.
Animal Health Component
50%
Research Effort Categories
Basic
50%
Applied
50%
Developmental
0%
Classification

Knowledge Area (KA)Subject of Investigation (SOI)Field of Science (FOS)Percent
30133101081100%
Knowledge Area
301 - Reproductive Performance of Animals;

Subject Of Investigation
3310 - Beef cattle, live animal;

Field Of Science
1081 - Breeding;
Goals / Objectives
Cattle Assisted Reproductive Technology (ART) has great promise, but suffers frompoor technical efficiency. The International Embryo Transfer Society publishes yearly data on the outcomes of cattle ART. Over the past decade, there has been a 350% increase in utilization, but a 7% decrease in the efficiency of embryo production from oocytes obtained. This is due to 'technical' problems, that is embryos do not grow well in laboratory incubators, and 'process' problems, where many incumbent cattle IVF companies require the transport of oocytes to out-of-stateregional laboratories for fertilization and embryo development and transport of embryos back to the recipient cows located on the farm or veterinarians site. There is a need for improved bovine embryo culture technology, which ReproHealth is developing. ReproHealth has created the world's 1st bovine IntraVaginal Embryo Culture (IVC) device, a technology used in humans successfully and FDA-approved, and plans to bring this technology, with modification, to cattle production.The Phase I Technical Objectives focus on identifying the best plastic to support embryo growth, a method for ensuring the IVC device stays in place while minimizing vaginal irritation and discharge, and demonstrating the revised design and new materials that can establish a pregnancy in a recipient cow. The Phase I Technical Objectives are as follows:Technical Objective 1: Determine the ideal composition of the plastic (polystyrene or polypropylene) that best supports embryo growth efficiency.Technical Objective 2: Develop a method for clipping the IVC capsule to a standard CIDR to keep the device in place.Technical Objective 3: Establish a pregnancy in a recipient cow with ReproHealth's IVC device.These Technical Objectives will support the validation and demonstrate the feasibility of the new approach. Demonstrated feasibility in Phase I will support a comparative study in Phase II among a larger population of cows. Phase I is designed to answer the following key technical questions:Does the composition of the plastic (polystyrene or polypropylene) alter the embryo growth efficiency?Does a clip-on IVC device holder, attached to a CIDR keep the device in place, and cause minimal vaginal irritation or discharge?Can we establish a pregnancy in a recipient cow, using standard recipient synchronization using an IVC device?
Project Methods
Technical Objective 1: Determine the ideal composition of the plastic (polystyrene or polypropylene) that best supports embryo growth efficiency.The device consists of an outer vessel and toinner chambers. The outer vessel keeps the inner embryo culture chamber free of vaginal microbes and allows the differential diffusion of CO2 to maintain the bicarbonate-buffered media in the inner culture chambers. To determine the plastic composition that is most advantageous for embryo growth differentprototypes will be made. The device consists of six components--two outer parts that serve as the outer sealed vessel and two inner chambers with lids that hold the growing embryos.To determine the ideal combination of plastics,both polystyrene and polypropylene plastic will be tested.ReproHealth will work with its contract mold manufacturer (Thunderbird Molding, Elkhart, IN) to produce aluminum molds for making prototypes. Aluminum molds are used for smaller runs and are not made for commercial-scale production. Once the prototypes have been produced in both polystyrene and polypropylene, ReproHealth will conduct quality control (QC) testing with a two-cell mouse embryo assay. The two-cell mouse assay is done for quality control of lab consumables typically used in common ART procedures like InVitro Fertilization. Briefly, the plastic to be tested, in this case, the embryo culture chambers, and our vessel are placed in an incubator with embryo culture media and the test mouse embryos. If > 80% of the embryos develop to the blastocyst stage, the plastic is deemed safe to use for the cattle embryos. This QC testing will be done in Dr. Donahue's laboratory using his conventional IVF incubators in Indianapolis. Typically, 20 mouse embryos are used for each QC test. All device parts are sterile and a commercially available continuous embryo culture media that has been validated to grow embryos to the blastocyst stage without the need for sequential media changes will be used in the device.Once we have confirmed the prototype devices are nontoxic they will be used in trials. Technical Objective 2: Develop a method for clipping the IVC capsule to a standard CIDR to keep the device in place.Prior studies indicated the need for the IVC device to be anchored to a holding device. While several prototypes were developed, the team--with input from potential end users--determined the CIDR offers a simple way to hold the IVC device in place. CIDRs are low-cost, ubiquitous, and complementary (delivering progesterone, an important hormone during early embryonic development) to the purpose of the IVC device.The PI and Dr. Dixon will complete the design of a reusable clip to hold the device flush with the CIDR. The clip must be composed of a biocompatible material that does not interfere with CIDR application. Using SolidWorks CAD (a design software), the team will design a clip-on holder and Thunderbird Molding will complete aluminum molds. Prototypes will be prepared using both medical-grade stainless and silicone.Next, the clip will be tested on Dr. Dixon's cows. The PI and Dr. Dixon will test the ability of the new design to hold the IVC device in place on the CIDR. CIDRs will be inserted into the vagina of seven cows under Dr. Dixon's ownership. Upon removal, Dr. Dixon will assess vaginal discharge and complete a full blood count to assess for signs of infection. Technical Objective 3: Establish a pregnancy in a recipient cow with ReproHealth's IVC device.Once we have completed the above prototype testing, it is necessary to demonstrate the feasibility of the proposed IVC device and holder to result in a pregnancy. Dr. Dixon will aspirate bovine oocytes using standard methodsfrom one of his cows. The donor and recipients will be synchronized.Recipients will have a CIDR removed, and heat will be assessed by the conventional method to time embryo transfer with the production of blastocyst-stage embryos created in the IVC device. ReproHealth's technology must work in the typical setting of a reproductive veterinarian or cattle producer that is set up to do on-site OPU (i.e. chute, minimal lab with warmer incubator, and dissecting stereomicroscopes). Bicarbonate buffered media requires CO2 to maintain pH in an acceptable range. HEPES buffered media does not require CO2 and can be used in non-CO2 incubators. HEPES buffered media is often used for oocyte transport and maturation. By eliminating the need for a CO2 incubator, our technology will be easier to use in most settings. The only requirement will be a warmed incubator to hold the media. We are using HEPES buffered media to allow extended maturation of oocytes and for fertilization to occur. The IVC device will have bicarbonate buffered media and the cow's dissolved CO2 will bring the pH to the appropriate level for optimal embryo growth. The protocol below will be performed on-site, in the veterinarian's facility or producers' facility using incubators that they already have on-site and used in conventional IVP. ReproHealth's Bovine IVC Lab Checklist follows:Day -2_____ Dish prep for IVM4WP 500ul media, 400 ul oil overlay, HEPES BO-IVM, 38.8 CComplete all formsDay-1_____ Oocyte collection and begin IVM in a warmer incubatorWash COC in HEPES BO-IVM in a 25mm dish with 2ml IVM media prepared 2h priorDocument the cumulus expansion pre-incubationTransfer oocytes to 4WP HEPES BO-IVM, 21h to 24hDay-0____ Begin Fertilization in a warmer incubatorThaw and count semen, document on forms; final concentration of 2M/mlDocument the cumulus expansion post-incubation on forms35 mm IVF wash dish, makeup 2 hours beforeTransfer COCs to wash dish, then to Fertilization dishPlace sperm in each drop/wellPrepare IVC media; place 1.5ml in 5ml capped tube in warmer; put IVC devices in warmerPrepare IVC Holding 4WP with oil, to hold the stripped zygotes before loading them into the deviceDay 1___ Begin intravaginal cultureVortex to remove COCsPlace zygotes in the 'holding' dish prior to loading into the devicePut IVC media in the device prior to loading.Day 7___ Remove the device from animals assess fertilization and prepare for embryo transferWarm HEPES transfer media 2 hours priorRemove devicePictures and embryo gradingPrep for ETCryopreserve embryos or continue culturePotential Pitfalls and Alternative Strategies: The risk of contamination of culture media is always present, even when using sterile techniques, media, and devices. There is the risk of sub-optimal embryo growth because of issues specific to a given donor, or even failed fertilization and embryo growth. Each failure will be evaluated with root cause analysis. The Phase II trial will include a comparative study with conventional bovine IVF companies using split oocytes from a single donor to evaluate the 'technical' and 'process' problems noted before.Technical ObjectiveMonthsResponsible PartyMilestones12345678Determine the ideal composition of the plastic (polystyrene or polypropylene) that best supports embryo growth efficiency.PI, DD, TMA useable hermetically sealed sterile device that grows embryos using a 2-cell mouse assayDevelop a method for clipping on the IVC capsule to a standard CIDR to keep the device in place.PI, DD, TMThe Clip-on holder fits on the CIDR, produces no irritation, and does not interfere with the insertionEstablish a pregnancy in a recipient cow with ReproHealth's IVC device.PI, DDViable transferrable bovine IVC embryos resulting in pregnancyPI = James Donahue, MD (ReproHealth); DD = Dave Dixon, DVM (ReproHealth); TM = Thunderbird Molding

Progress 07/01/24 to 02/28/25

Outputs
Target Audience:The target audience for our bovine Intra Vaginal Embryo Culture (IVC) device includes producers currently using conventional bovine Assisted Reproductive Technology (ART). These technologies include Artificial Insemination (AI), Embryo Transfer and Flushing (ET), and In Vitro Production (IVP). The most recent IETS report showedthat only 21% of the eggs collected produce a viable embryo. On average, only fourembryos are produced per procedure. Based on this data, many producers will have no viable embryos. Our project is geared towards improving this reproductive technology inefficiency. There is much interest from the interactions we have had as described below. This project is bringing a new form of cattle ART to the market. While IVC has been used successfully in humans, it was only attempted about 25 years ago in cows, and the embryos were arrested at the early cleavage stage. We are the 1st to have made a blastocyst-stage embryo in one of our early prototype trials. Given this backdrop, we are creating a technology that can be easily used by the producers and/or veterinarians who work with them. Target audience: Large animal reproductive veterinarians Beef producers Dairy producers Show cow participants Each audience has used IVP to some degree and is interested in trying new technology to improve the rapid enhancement of their herd through better breeding technology. Since July 2024 we have been in front of several diverse Ag audiences. In August we were one of the five finalists in the Elevate Ventures Rally-IN 2024 Ag and food innovations competition. This conference had over 3000 attendees in Indianapolis with a significant number related to Ag innovation. We participated in the quarterly meetings of Agrinovus Indiana, an Ag not-for-profit in our state. Here we meet face to face with various stakeholders. We presented a talk about the intersection of human and animal medicine at one of the recent meetings. Our company was featured in Hoosier Ag Today, a statewide publication this Fall. Earlier this year we were one of the Farm Bureau 2024 Ag Innovation Challenge Companies (we made the final four!) and we keep nurturing our relationship, as the Farm Bureau touches so many people in Agriculture. We have been working with LARTA on customer discovery, for the eventual Phase II SBIR grant that we will submit in early 2025. We were invited to apply to the 2025 SXSW Ag innovation conference in Austin, TX and we are waiting to hear back from them as I write this update. Lastly, we just found out that our company is one of the finalists for the Indiana Mira Awards for Ag Innovation. This is quite an honor for us. We continue to be a portfolio company of AgLaunch365. Through the Ag Ventures Alliance and the Farmers Fund, we have received investments from farmers, who will be our eventual users. They will be doing paid trials of our technology. It is hoped that this will be in Spring, 2025 in OK and TN. Changes/Problems:The only change that we have is the trial of the semen separation device to compare it to density gradient centrifugation. This is a minor protocol change and because the device has two culture chambers we can make a direct comparison with the same lot of eggs and semen. This was approved by Section Director Bob Smith, DVM. We will still use the density gradient separation per the initial protocol. What opportunities for training and professional development has the project provided?We have been working with several biomedical engineering students at CalPoly on early iterations of the newly designed semen separation device. This gives them some real-world experience with device design and development. How have the results been disseminated to communities of interest?At several of the events listed previously, we have presented some preliminary data. We are working with AgLaunch 365 and they are aware of our progress. What do you plan to do during the next reporting period to accomplish the goals? Technical Objective 1. We plan to use the device in cattle. The device has 2 embryo culture chambers. This will allow us to test the semen separation device and compare it to the density gradient centrifugation. During December 2024 we will polish the aluminum molds and use sonic cleaning to reduce the debris that we noted in our quality control testing of the 1st set of devices. This should improve the embryo growth. We plan to compare the initial polystyrene devices with polypropylene devices. The gad permeability is different for both, and we will begin the production of these polypropylene devices in early 2025. Technical Objective 2. We will confirm that the balling gun applicator works well to deliver the CIDR attached IVC device to the cow vagina. It is more streamlined than other potential options. Technical Objective 3. This will be the most important step, to confirm a pregnancy. We will synch 2-3 recipients so that we may do fresh transfers of embryos per routine. We will be able to cryopreserve embryos as well as document the quality of the IVC derived embryos. We will also be working with LARTA to submit the Phase II SBIR grant. We will hopefully be presenting at SXSW and we will be at the Mira Awards Ceremony in February 2025 as one of the Ag Innovation Finalists.

Impacts
What was accomplished under these goals? Technical Objective 1. ReproHealth is creating a bovine intravaginal embryo culture device. This device has several requirements. The device must be made of a plastic similarto conventional IVF polystyrene culture dishes. It must be non-toxic and allow CO2 and O2 to pass through the walls to modulate and support the bicarbonate-buffered embryo culture media pH and cellular respiration. It must be small enough to fit inside the cow vagina without causing vaginal discharge or irritation. Finally, it must be able to be attached to the CIDR, which is commonly used in bovine reproduction and creates a high progesterone environment, which is typically found in early gestation. In July 2025 we began a redesign of the device to include a small hole at the ends to be used to connect the device to the CIDR and we added small wings to the outer chamber to make it easier to seal the device prior to inserting it into the cow vagina. Preliminary manufacturability testing was done in September to begin the production of the Injection Molding molds that would eventually make the devices that we would use in the animal studies and sell to customers. The mold makes all six components of the device: 2 embryo culture wells, 2 lids for the wells, and 2 parts for the outer chamber that seals the device to keep vaginal flora from getting in and contaminating the culture media. There are additional silicone seals on each culture chamber to keep contamination risk low. The aluminum mold that was created produces all six parts in about 45 seconds. We received the 1st set of parts at the end of November and began Quality Control (QC) testing using the 2-cell mouse embryo assay. The human version of the IVC device uses similar QC testing. This was in vitro testing to confirm that the device would grow embryos in a CO2 incubator. Briefly, the assay involves taking 1.8 ml of pre-equilibrated culture media and placing it in each culture chamber. 2-cell mouse embryos were then thawed, 8 embryos were placed in each chamber and 4 embryos were placed in a Petri dish to be used as a control. The device was then closed and placed in the outer chamber. The seal felt very secure. The device was placed on its side in a CO2 incubator. In 5 days, we examined the contents. 70% of the 2-cell embryos became blastocysts in the device. This was slightly less than the control. We did note that there was some plastic debris and 'shards' inside the culture media. It is possible that the debris from manufacturing had a negative effect, but still, we had blastocysts development meaning the concept and plastic are working as we hoped. We immediately met with the team at Thunderbird Molding of Elkhart, IN, the manufacturer, regarding this issue. They are working to polish the molds and to make them sterile in clean rooms. This will happen during the month of December 2025. This should be in time for animal trials during January through February 2025. While were waiting for the device molds to be created, a 12-week process, we drew our attention to other factors that may affect embryo production in IVP, specifically semen preparation. I sent a letter to the Section Director, Bob Smith, DVM, to see if we could make this change to the protocol, and he agreed that we could. It will not change the actual grant needs, as the design and prototypes will be minimal in cost and can be shifted from other grant funding sections. Most IVP semen prep is done with density gradient centrifugation (DGC). DGC involves a silica nano-particle colloid suspension with an upper layer of 45% and a lower layer of 90% silica particles. Silica particles are charged and have been shown to bind the charged surface of the spermatozoa. The semen specimen is placed on the top of the colloid gradient (i.e. Percoll, Pure-Sperm, etc.) in a 15 ml conical centrifuge test tube and then centrifuged for 15-20 minutes at 300 x the force of gravity. The g-forces will pull the 'purified' spermatozoa down to the bottom of the tube. It is well known that DGC can damage spermatozoa and lead to poor embryo growth in human IVF. We wanted to develop a semen filter device that would not use silica nano-particles or centrifugation. There are human fertility corollary devices. We designed a simple filter device with a structure that fits into the 15 ml conical test tube. The best semen 'swim up,' and separates themselves from abnormal spermatozoa that have lower potential for fertilization, all without centrifugation. Initial trials are positive. When bovine semen is placed in the 15 ml conical test tube and we use either an etched polycarbonate membrane or a PET (Polyethylene terephthalate) 15 um membrane, we see improved motility of the specimen. This would presumably lead to better fertilization and embryos. About 2 weeks ago we tried this on freshly retrieved bovine oocytes after maturation. Unfortunately, the fertilization was quite poor. We believe this is due to the high concentration of glycerol used as a cryoprotectant of semen. This may be an issue going forward. We will try again and try to remove the glycerol prior to processing. This is a start, however. If we are able to process better specimens, we may be able to improve AI, as well. While not part of this project, we will make a larger device to fit into 50 ml conical tubes for boar semen purification. We tried one sample and found improved motility with extended semen, but this was a single trial. Technical Objective 2. We have been working on how to attach the device to the CIDR. We have used a zip tie and other options to attach the device to the backbone of the CIDR. Using a conventional CIDR applicator it goes into the cow vaginal pretty well with little discomfort. With the newly designed device, we have recently come up with the idea to use a modified balling gun. We added a 1.25 " silicone tube to the end of the gun, and the device fits inside and it attached to the 2 mm hole at the top of the CIDR in the middle of the wings. When we push the plunger of the balling gun, the CIDR is released and the device is placed inside the vagina. This is a more streamlined applicator setup compared to attaching the IVC device to the CIDR backbone. We are currently seeing how well this works. Technical Objective 3. At this time, we have not placed embryos in synched recipients. This is planned for the 1st of the year.

Publications